126 related articles for article (PubMed ID: 28913367)
1. Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-
Li W; Xu L; Wang Y; Zhao L; Kellner DB; Gao Q
J Immunol Res; 2017; 2017():1092507. PubMed ID: 28913367
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
3. Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients.
Zhang Y; Zhu Y; Zhao E; He X; Zhao L; Wang Z; Fu X; Qi Y; Ma B; Song Y; Gao Q
Immunotherapy; 2017 Nov; 9(14):1165-1174. PubMed ID: 29067881
[TBL] [Abstract][Full Text] [Related]
4. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
[TBL] [Abstract][Full Text] [Related]
6. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
Lin M; Liang S; Jiang F; Xu J; Zhu W; Qian W; Hu Y; Zhou Z; Chen J; Niu L; Xu K; Lv Y
Immunol Lett; 2017 Mar; 183():37-43. PubMed ID: 28143792
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
9. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumor infiltrating lymphocytes in melanoma.
Burton AL; Roach BA; Mays MP; Chen AF; Ginter BA; Vierling AM; Scoggins CR; Martin RC; Stromberg AJ; Hagendoorn L; McMasters KM
Am Surg; 2011 Feb; 77(2):188-92. PubMed ID: 21337878
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
[TBL] [Abstract][Full Text] [Related]
14. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.
Håkansson A; Gustafsson B; Krysander L; Hjelmqvist B; Rettrup B; Håkansson L
Br J Cancer; 2001 Dec; 85(12):1871-7. PubMed ID: 11747328
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
Khammari A; Nguyen JM; Pandolfino MC; Quereux G; Brocard A; Bercegeay S; Cassidanius A; Lemarre P; Volteau C; Labarrière N; Jotereau F; Dréno B
Cancer Immunol Immunother; 2007 Nov; 56(11):1853-60. PubMed ID: 17549472
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery.
Zheng K; Tan JM; Wu WZ; Qiu YM; Zhang H; Xu TZ; Sun XH; Zhuo WL; Wang D; Zhang JP
J BUON; 2015; 20(2):505-13. PubMed ID: 26011343
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
19. Perspective on allogeneic melanoma lysates in active specific immunotherapy.
Mitchell MS
Semin Oncol; 1998 Dec; 25(6):623-35. PubMed ID: 9865677
[TBL] [Abstract][Full Text] [Related]
20. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.
Creagan ET; Dalton RJ; Ahmann DL; Jung SH; Morton RF; Langdon RM; Kugler J; Rodrigue LJ
J Clin Oncol; 1995 Nov; 13(11):2776-83. PubMed ID: 7595738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
